The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy—from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for the Journal for ImmunoTherapy of Cancer, an outlet devoted to and created by today's leaders in the field.
Read the Journal
JITC is indexed in six major indexing sources, including PubMed, PubMed Central, MEDLINE, the Directory of Open Access journals, Scopus, and Thomson Reuters’ Emerging Sources Citation Index (ESCI). The ESCI is part of the robust Web and Science collection, the world’s largest compilation of research data, books, journals, proceedings, publications and patents.
As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer society members waived article processing charges for manuscripts accepted through 2017.
To take advantage of this member benefit, contact SITC at +1 414-271-2456 or firstname.lastname@example.org for your member code.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm, and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding...
Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies; however, following availability of PK data, the need for weight-based dosing for pembrolizumab was reassessed...
We have a patient with multiple brain metastases from melanoma beginning to develop symptoms (mental slowing and right facial droop) as we try to get him precerted for checkpoint inhibitor therapy. Any thoughts/anecdotes/data about how much if any ...
Did you know there are more than 800 resources available to SITC members? Access by your user type ( researcher , clinician , patient ) or by using the SITC Cancer Immunotherapy CONNECT Search (top right) to find exactly what you're looking ...
In light of what can occur in the TME in the steady state, malignant cells killed by intrinsic/extrincic stress factors in it can lead to danger-associated molecular patterns (e.g. HMGB-1) and plasma membrane exposure of the endoplasmic reticulum (ER) ...
Thank you everyone.Very helpful. ------------------------------ Jane Gutkovich Director of Research The EHE Foundation Woodbridge VA ------------------------------
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com